Evidence map›Paper›PMID 26640610›Full record

ArticleCancer and clinical oncology2013

Reasons to Use and Disclose Use of Complementary Medicine Use - An Insight from Cancer Patients.

Kristen Arthur, Juan Carlos Belliard, Steven B Hardin, Kathryn Knecht, Chien-Shing Chen, Susanne Montgomery

Open access · hybridAbstract read
In one paragraph

Article in Cancer and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Integrative medicine and the oncology patient: options and benefits.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  15. Implicit Reasons for Disclosure of the Use of Complementary Health Approaches (CHA): a Consumer Commitment Perspective.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kristen ArthurSchool of Public Health, Loma Linda University, Loma Linda, CA, USA.
Juan Carlos BelliardSchool of Public Health, Loma Linda University, Loma Linda, CA, USA.
Steven B HardinSchool of Medicine, Loma Linda University, Loma Linda, CA, USA.
Kathryn KnechtSchool of Pharmacy, Loma Linda University, Loma Linda, CA, USA.
Chien-Shing ChenSchool of Medicine, Loma Linda University, Loma Linda, CA, USA.
Susanne MontgomerySchool of Public Health, Loma Linda University, Loma Linda, CA, USA.
Loma Linda University · US

Funding

The role of imidazoline receptor in type-2 diabetesP20MD001632 · NIMHD · LOMA LINDA UNIVERSITY · PI DELEON, DAISY · 2005 to 2009
$8.0M
Research Training/Education CoreP20MD006988 · NIMHD · LOMA LINDA UNIVERSITY · PI DE LEON, MARINO · 2012 to 2016
$6.2M
NIMHD NIH HHS P20 MD001632NIMHD NIH HHS P20 MD006988
6 · The paper itself

Abstract

Studies have shown a high prevalence (40-83%) of complementary and alternative medicine (CAM) use among cancer patients in the U.S.A cross-sectional, mixed-methods pilot study was completed. This paper focuses on the quantitative analysis conducted on demographic predictors of complementary medicine (CM) use, reasons to use CM, and disclosure to healthcare provider data. Surveys were interview-administered at the Loma Linda University Medical Center Cancer Center. Participants, 18 years or older, were selected from a convenient sample. Eighty-seven percent (87.9%) of participants reported to have used CM as a cancer treatment and most reported to have used it "to help fight the cancer." Women were eight-times more likely to use prayer. All non-Caucasian and Hispanic participants reported to use CM as a cancer therapy and none reported to use a CM provider. More women (72%) disclosed their CM use than men (53.3%). Different prevalences and predictors exist when differentiating CM modalities, reasons to use CM vary by gender, and disclosure proportions vary by gender.

Indexed as

cancer therapiesComplementary and Alternative Medicine (CAM)Complementary Medicine (CM)disclosure of CAM

Identifiers

PMID26640610
PMCPMC4667734
OpenAlexW2093901192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.